290 related articles for article (PubMed ID: 33038239)
1. Association of previous treatment with anti-tumour necrosis factor inhibitors with the effectiveness of secukinumab in the treatment of psoriatic arthritis: systematic review and meta-analysis.
Xu Y; Li Y; Dong M; Gao Z; Chen X; Liu H; Shen M
Rheumatology (Oxford); 2020 Dec; 59(12):3657-3665. PubMed ID: 33038239
[TBL] [Abstract][Full Text] [Related]
2. Does previous use of tumour necrosis inhibitors change the therapeutic effect of interleukin (IL)-17 or IL-12/23 inhibitors on psoriasis and psoriatic arthritis? Results of a systematic review.
Xie Y; Liu Y
Clin Exp Dermatol; 2022 Sep; 47(9):1627-1635. PubMed ID: 35466472
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of Subcutaneous Secukinumab in Patients with Active Psoriatic Arthritis Stratified by Prior Tumor Necrosis Factor Inhibitor Use: Results from the Randomized Placebo-controlled FUTURE 2 Study.
Kavanaugh A; McInnes IB; Mease PJ; Hall S; Chinoy H; Kivitz AJ; Wang Z; Mpofu S
J Rheumatol; 2016 Sep; 43(9):1713-7. PubMed ID: 27307536
[TBL] [Abstract][Full Text] [Related]
4. Comparative effectiveness of abatacept, apremilast, secukinumab and ustekinumab treatment of psoriatic arthritis: a systematic review and network meta-analysis.
Kawalec P; Holko P; Moćko P; Pilc A
Rheumatol Int; 2018 Feb; 38(2):189-201. PubMed ID: 29285605
[TBL] [Abstract][Full Text] [Related]
5. Comparison of treatment retention and response to secukinumab versus tumour necrosis factor inhibitors in psoriatic arthritis.
Lindström U; Glintborg B; Di Giuseppe D; Schjødt Jørgensen T; Gudbjornsson B; Lederballe Grøn K; Aarrestad Provan S; Michelsen B; Lund Hetland M; Wallman JK; Nordström D; Trokovic N; Love TJ; Krogh NS; Askling J; Jacobsson LTH; Kristensen LE
Rheumatology (Oxford); 2021 Aug; 60(8):3635-3645. PubMed ID: 33367900
[TBL] [Abstract][Full Text] [Related]
6. Retention rate and effectiveness of secukinumab vs TNF inhibitor in ankylosing spondylitis patients with prior TNF inhibitor exposure.
Min HK; Kim HR; Lee SH; Hong YS; Kim MY; Park SH; Kang KY
Rheumatology (Oxford); 2021 Dec; 60(12):5743-5752. PubMed ID: 33725088
[TBL] [Abstract][Full Text] [Related]
7. Secukinumab provides sustained PASDAS-defined remission in psoriatic arthritis and improves health-related quality of life in patients achieving remission: 2-year results from the phase III FUTURE 2 study.
Coates LC; Gladman DD; Nash P; FitzGerald O; Kavanaugh A; Kvien TK; Gossec L; Strand V; Rasouliyan L; Pricop L; Ding K; Jugl SM; Gaillez C;
Arthritis Res Ther; 2018 Dec; 20(1):272. PubMed ID: 30526678
[TBL] [Abstract][Full Text] [Related]
8. Secukinumab Efficacy on Psoriatic Arthritis GRAPPA-OMERACT Core Domains in Patients with or Without Prior Tumor Necrosis Factor Inhibitor Use: Pooled Analysis of Four Phase 3 Studies.
Orbai AM; Husni ME; Gladman DD; Leung YY; Siebert S; Tillett W; Vis M; Chambenoit O; Meng X; Mease PJ
Rheumatol Ther; 2021 Sep; 8(3):1223-1240. PubMed ID: 34218429
[TBL] [Abstract][Full Text] [Related]
9. Improvement from ixekizumab treatment in patients with psoriatic arthritis who have had an inadequate response to one or two TNF inhibitors.
Kirkham B; Sesin C; Gellett AM; Sprabery AT; Lin CY; Turkiewicz A
Rheumatology (Oxford); 2021 Sep; 60(9):4367-4372. PubMed ID: 33479721
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of secukinumab in active rheumatoid arthritis with an inadequate response to tumor necrosis factor inhibitors: a meta-analysis of phase III randomized controlled trials.
Huang Y; Fan Y; Liu Y; Xie W; Zhang Z
Clin Rheumatol; 2019 Oct; 38(10):2765-2776. PubMed ID: 31087226
[TBL] [Abstract][Full Text] [Related]
11. Effects of ustekinumab on spondylitis-associated endpoints in TNFi-naïve active psoriatic arthritis patients with physician-reported spondylitis: pooled results from two phase 3, randomised, controlled trials.
Helliwell PS; Gladman DD; Chakravarty SD; Kafka S; Karyekar CS; You Y; Campbell K; Sweet K; Kavanaugh A; Gensler LS
RMD Open; 2020 Feb; 6(1):. PubMed ID: 32209721
[TBL] [Abstract][Full Text] [Related]
12. Secukinumab real world drug retention compared to TNF-alpha inhibitors in psoriatic arthritis.
Eviatar T; Zisman D; Gendelman O; Reitblat T; Balbir-Gurman A; Mashiach T; Almog R; Elkayam O
Clin Exp Rheumatol; 2022 Jan; 40(1):15-23. PubMed ID: 33427613
[TBL] [Abstract][Full Text] [Related]
13. Comparative Effectiveness of Bimekizumab and Secukinumab in Patients with Psoriatic Arthritis at 52 Weeks Using a Matching-Adjusted Indirect Comparison.
Mease PJ; Warren RB; Nash P; Grouin JM; Lyris N; Willems D; Taieb V; Eells J; McInnes IB
Rheumatol Ther; 2024 Mar; ():. PubMed ID: 38446397
[TBL] [Abstract][Full Text] [Related]
14. Secukinumab: A Review in Psoriatic Arthritis.
Blair HA
Drugs; 2021 Mar; 81(4):483-494. PubMed ID: 33661486
[TBL] [Abstract][Full Text] [Related]
15. Discontinuation and switching patterns of tumour necrosis factor inhibitors (TNFis) in TNFi-naive and TNFi-experienced patients with psoriatic arthritis: an observational study from the US-based Corrona registry.
Mease PJ; Karki C; Liu M; Li Y; Gershenson B; Feng H; Hur P; Greenberg JD
RMD Open; 2019; 5(1):e000880. PubMed ID: 31168408
[TBL] [Abstract][Full Text] [Related]
16. Improvement in patient-reported outcomes and work productivity following 3-year ustekinumab or tumour necrosis factor inhibitor treatment in patients with psoriatic arthritis: results from the PsABio real-world study.
Gossec L; Siebert S; Bergmans P; de Vlam K; Gremese E; Joven-Ibáñez B; Korotaeva TV; Lavie F; Noël W; Nurmohamed MT; Sfikakis PP; Sharaf M; Theander E; Smolen JS
Arthritis Res Ther; 2023 Jun; 25(1):109. PubMed ID: 37353788
[TBL] [Abstract][Full Text] [Related]
17. Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial.
McInnes IB; Behrens F; Mease PJ; Kavanaugh A; Ritchlin C; Nash P; Masmitja JG; Goupille P; Korotaeva T; Gottlieb AB; Martin R; Ding K; Pellet P; Mpofu S; Pricop L;
Lancet; 2020 May; 395(10235):1496-1505. PubMed ID: 32386593
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3).
Nash P; Mease PJ; McInnes IB; Rahman P; Ritchlin CT; Blanco R; Dokoupilova E; Andersson M; Kajekar R; Mpofu S; Pricop L;
Arthritis Res Ther; 2018 Mar; 20(1):47. PubMed ID: 29544534
[TBL] [Abstract][Full Text] [Related]
19. Cost-Effectiveness of Secukinumab Versus Other Biologics in the Treatment of Psoriatic Arthritis: An Argentinean Perspective.
Aiello E; Bianculli PM; Bhattacharyya D; Gunda P; Citera G
Value Health Reg Issues; 2019 Dec; 20():86-94. PubMed ID: 31103950
[TBL] [Abstract][Full Text] [Related]
20. Comparative efficacy and safety of secukinumab, ixekizumab, and tofacitinib in patients with active psoriatic arthritis showing insufficient response to tumor necrosis factor inhibitors.
Song GG; Lee YH
Int J Clin Pharmacol Ther; 2021 Jul; 59(7):511-518. PubMed ID: 33835018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]